NCT04540042View on ClinicalTrials.gov

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

December 21, 2021

Study Completion Date

January 13, 2022

Conditions
AsthmaChronic Obstructive Pulmonary Disease
Interventions
DRUG

SelK2 (Part 1)

I.V., multiple-dose (Day 1 and Day 22)

DRUG

Placebo (Part 1)

I.V., multiple-dose (Day 1 and Day 22)

DRUG

SelK2 (Part 2)

I.V., single-dose (Day 1)

DRUG

Placebo (Part 2)

I.V., single-dose (Day 1)

Trial Locations (2)

Unknown

Queen Anne Street Medical Centre, London

Medicines Evaluation Unit Ltd., Manchester

All Listed Sponsors
lead

Tetherex Pharmaceuticals Corporation

INDUSTRY

NCT04540042 - Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) | Biotech Hunter | Biotech Hunter